A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
Public ClinicalTrials.gov record NCT01859741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.
Study identification
- NCT ID
- NCT01859741
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 172 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2012 (Actual)
- Primary completion
- Apr 18, 2017 (Actual)
- Completion
- May 8, 2017 (Actual)
- Last update posted
- Sep 9, 2020
2012 – 2017
United States locations
- U.S. sites
- 35
- U.S. states
- 22
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Sarah Cannon | Fort Myers | Florida | 33905 | — |
| Ocala Oncology Center, PL | Ocala | Florida | 34474 | — |
| Piedmont Cancer Institute | Atlanta | Georgia | 30318 | — |
| Georgia Cancer Specialists, PC | Atlanta | Georgia | 30341 | — |
| Univeristy of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| University of Maryland, Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21231 | — |
| Weinberg Cancer Institute | Baltimore | Maryland | 21237 | — |
| University of Michigan Medical Center, Clinical Trials Office | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Minnesota Oncology Hematology , P.A. | Minneapolis | Minnesota | 55404 | — |
| Oncology Hematology West PC, dba Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| Providence Cancer Center Oncology and Hematology Care Eastside | Portland | Oregon | 97213 | — |
| UPMC Cancer Pavilion | Pittsburgh | Pennsylvania | 15232 | — |
| Greenville Health System, Clinical Research Unit, Institute for Translational Oncology Research | Greenville | South Carolina | 29605 | — |
| Tennessee Oncology, PLLC | Chattanooga | Tennessee | 37404 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology-South Austin | Austin | Texas | 78745 | — |
| Texas Oncology-Bedford | Bedford | Texas | 76022 | — |
| Texas Oncology, P.A. | Dallas | Texas | 75246 | — |
| The University of Texas MD A nderson Cancer Center | Houston | Texas | 77030 | — |
| Cancer Care Network of South Texas | San Antonio | Texas | 78217 | — |
| Oncology and Hematology Associates of Southwest Virginia Inc. | Blacksburg | Virginia | 24060 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01859741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2020 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01859741 live on ClinicalTrials.gov.